A framework for genomic biomarker actionability and its use in clinical decision making - Test2 - elhamkhani - TriplyDB

A framework for genomic biomarker actionability and its use in clinical decision making

A framework for genomic biomarker actionability and its use in clinical decision making

http://www.wikidata.org/entity/Q34781122

about

Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay An informatics research agenda to support precision medicine: seven key areas Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.Genomic landscape of salivary gland tumors.Actionability and precision oncology.From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.

P2860

Q33873653-854F9A71-EA60-4908-8714-6F1332D74CC5 Q36962764-51CF703A-C4B1-42FE-93F6-DA99D91DA1A3 Q37051399-068D87BB-457A-47C9-B5C8-5EEC10C0A094 Q38679628-836979EA-E807-4E41-A1CB-915EADBCC01C Q41133627-0E2D5E3D-D498-4C18-82ED-010DC8890214 Q41546576-8D5C4358-D15D-4430-8F5D-9B0B8FC86A24 Q41886148-1EE0122A-9E4F-4660-A12A-740E8F973E30 Q52354170-E8C8246C-5F27-4A59-B181-670EEF0D5736

P2860

A framework for genomic biomarker actionability and its use in clinical decision making

http://www.wikidata.org/entity/Q34781122

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A framework for genomic biomarker actionability and its use in clinical decision making

@ast

A framework for genomic biomarker actionability and its use in clinical decision making

@en

A framework for genomic biomarker actionability and its use in clinical decision making

@nl

type

label

A framework for genomic biomarker actionability and its use in clinical decision making

@ast

A framework for genomic biomarker actionability and its use in clinical decision making

@en

A framework for genomic biomarker actionability and its use in clinical decision making

@nl

prefLabel

A framework for genomic biomarker actionability and its use in clinical decision making

@ast

A framework for genomic biomarker actionability and its use in clinical decision making

@en

A framework for genomic biomarker actionability and its use in clinical decision making

@nl

P1433

Q34781122-EB264AAD-01BD-4B33-9EA9-9D4009222FDA

P1476

Q34781122-EEEFFAC7-B938-426B-9AE3-A27EEEA033ED

P2093

Q34781122-14162168-9762-4465-B9E4-2F6DC3378CC1

Q34781122-1A70AD9F-3A30-4BE5-9EAD-9C840DFB87E1

Q34781122-2CEEEC2B-7EA4-4C6C-958E-58DD62B0601F

Q34781122-398EF881-7D15-4584-975D-991868613699

Q34781122-48B9C777-BE13-475A-B7B9-C20B5AA25F6C

Q34781122-7B4B0D78-21AB-4312-BDD6-881941C6108F

Q34781122-AB20E1F9-BCCC-4A1D-9086-4608BD922242

Q34781122-F9CD755C-F4F6-4B14-8143-A040FDE58E07

Q34781122-FAFA6B1F-BCD9-4862-BFA0-D93EB2E8B59C

P2860

Q34781122-0A327AFD-895E-4461-A15E-5025D3A37A0B

Q34781122-0C5B8E52-A13F-4F24-B953-5897F9413536

Q34781122-109A615E-553B-4CF9-AB77-61FA288EB4DC

Q34781122-13F5CE85-5B1F-4036-A06A-E9F968DF9D87

Q34781122-1AD8BCA1-6C7D-43BA-BD52-E6C188910DB4

Q34781122-1D6D5970-58CA-4B55-9238-1BD2FF7DF7B9

Q34781122-204E7CA5-03B3-48D8-A9F0-6368B2135735

Q34781122-24C1363F-ED61-42C6-A779-9ECC4C5F4400

Q34781122-26E7E05F-1C66-41BD-A30F-A5B7837EED2F

Q34781122-2A9AE9A5-F23C-4F21-839F-655BCA161D8B

P304

Q34781122-43C363AD-D3F4-4D10-8AF3-7E62699B4C3A

P31

Q34781122-16CA2A2C-7D4E-4508-8695-CAC6B1C7985E

P356

Q34781122-0AFACECE-3B3F-4809-A13F-3E09183423F6

P433

Q34781122-08386AE9-CCC8-4B05-B595-BE8E3BFAC9C2

P478

Q34781122-CD03DDFB-1060-4700-9F4E-C23832FE6468

P50

Q34781122-12EFC80C-7BA6-4790-AE78-8DC4BA231C2C

Q34781122-72FD295E-CFC4-4890-8653-4E9D8188D7D4

Q34781122-AF36407A-9EDE-443C-913D-394587E66382

P577

Q34781122-F532A965-119C-4D46-B6B2-F2ECC8DDA010

P698

Q34781122-800FF850-2DBF-4A1E-9B37-3CCFB0307C99

P921

Q34781122-102185E9-4948-498C-9B21-A4F9CC5420B9

P932

Q34781122-05BEDA3C-CB5A-4002-8527-F94D69403BA9

P356

P1433

P1476

A framework for genomic biomarker actionability and its use in clinical decision making

@en

P2093

Filip Janku

http://www.w3.org/2001/XMLSchema#string

Ignacio Garrido-Laguna

http://www.w3.org/2001/XMLSchema#string

Javier Munoz

http://www.w3.org/2001/XMLSchema#string

Jordi Rodon

http://www.w3.org/2001/XMLSchema#string

Michelle L Turski

http://www.w3.org/2001/XMLSchema#string

Razelle Kurzrock

http://www.w3.org/2001/XMLSchema#string

Richard Schwab

http://www.w3.org/2001/XMLSchema#string

Smruti J Vidwans

http://www.w3.org/2001/XMLSchema#string

Vivek Subbiah

http://www.w3.org/2001/XMLSchema#string

P2860

Passenger deletions generate therapeutic vulnerabilities in cancer

Mammalian target of rapamycin: a central node of complex signaling cascades

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

P304

614-623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOSCIENCE.90

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Ignacio Garrido-Laguna

P577

2014-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25593991

http://www.w3.org/2001/XMLSchema#string

P921

P932

4278279

http://www.w3.org/2001/XMLSchema#string